earnings

13th July 2011 Fondaparinux was approved by the FDA

4th August 2011 Alchemia’s Drug is launched

27th October 2011 ACL announced that Dr Reddys had a market share of 10% “This equates to 740,000 or there abouts a week” They would of hit the ground running

6th February 2012 ACL announced that Dr Reddys had a market share of 18% representing 1.4 Million a week.
The same announcement touted that Reddys had 30% of the retail segment which was worth a robust $240Million this divided by 52 Weeks is 4.6 Million a week 30% of 4.6 Million is in fact 1.4 Million a week as stated in the announcement

Remember they targeted the retail segment first because it was more profitable.

So if will take a estimate,

4th August to sometime in say mid December equates to sales of 740K per week.
That’s 18 Weeks at $740,000 = 13.3 Million

December to March sales were 18% or 1.4 Million a week
That’s 14 Weeks at 1.4Million equals 19.6 Million

That’s a total of 33 million. Divided by 3, being 1.Cost of Goods 2. Dr Reddys, 3. Alchemia With ACL earning 11 Million

My guess would be that an announcement will come at the end of May 60 days after Dr Redys Quarterly as per the terms of the agreement.

It will state that Reddys has been repaid (what we believe to be 9 Million) and ACL has received a chq for 2 to 3 Million could be more as it would have been a incremental weekly increase between 740K and 1.4 Million.

At this point ACL would be able to put a forward estimate of earnings for the next financial Year at 28 Million formally known as Guidance.

We will then be re-rated, its only 2 weeks to go